Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
US10471063B2 · kind B2 · utility
7Cited by
5References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2017 |
| Grant date | Nov 12, 2019 |
| Priority date | — |
| Expiry date | Jun 5, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2202/064
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.